X-Ray Analyses

A Buffett-lens X-ray of AMZN at $247: the everything store, the toll booth on two million sellers, and the railroad of the AI era — revenue up 5× in a decade, profit up 33×, and free cash flow now negative as a ~$200B capex bet swallows every dollar. A wonderful flywheel that has never paid its owners a cent — and asks for a decade of faith.

A Buffett-lens X-ray of BofA at $58: one of America's Big Four banks, built on a ~$2-trillion low-cost deposit base — banking's version of float. ~14× earnings and 1.4× book with a ~13% return on tangible equity. A fine, cheap-looking bank — but banks are leveraged and cyclical, it sits near its highs, and even Buffett has been trimming.

A Buffett-lens X-ray of Amex at $348: the closed-loop, spend-centric network — it issues, lends, and sees both sides of every swipe. A premium-brand moat around affluent spenders, Berkshire's untouched ~21% stake, and ~21× earnings for double-digit growth — cheaper than Visa, but it carries credit risk Visa never touches.

A Buffett-lens X-ray of Apple at $294: the most valuable company on earth and one of the great consumer franchises — a brand-and-ecosystem moat, a fortress balance sheet, and the largest buyback in history. The catch is the price: ~35× earnings for mid-single-digit growth, and even Buffett trimmed.

A Buffett-lens X-ray of Salesforce at $157: the world's #1 CRM, ~43% below its high on AI-disruption fear — now ~10× free cash flow, ~17× earnings, with a deep switching-cost moat and a fixed-up balance of margins. A wonderful franchise on sale, if the fear is overblown.

A Buffett-lens X-ray of BAT at $60: perhaps the clearest case of a wonderful business in a terrible industry — a penny-to-make, dollar-to-sell cash machine yielding ~5.3%, but with declining volumes, £87B of acquisition goodwill and an ESG stain. The easy money has already been made.

A Buffett-lens X-ray of Visa at $343: perhaps the purest toll booth in public markets — a 51% net margin, a two-sided network no rival can rebuild, and double-digit growth as cash keeps dying. The catch is the price: ~30× earnings leaves a thin margin of safety.

A Buffett-lens X-ray of ARE at $53 — a deep-value special situation. The pioneer of lab real estate trades at ~0.5× book after a 71% crash, a 45% dividend cut and $1.4B of impairments — yet founder Joel Marcus is buying. Contrarian bargain or value trap? A cheap asset with still-falling fundamentals.

A Buffett-lens X-ray of O at $62 — and a lesson in reading a REIT. The headline P/E of 51× and 265% payout are illusions; on the right metric (AFFO) it trades at ~15× with a well-covered 5.2% monthly yield. A dependable, bond-like income compounder at a fair price — own it for the cheque, not the capital gain.

A Buffett-lens X-ray of GOOGL at $357: a toll-booth on the world's information — ~90% search share, YouTube, a top-tier AI lab and Waymo — now at a fair ~27× earnings, but facing its first real test: does AI answer-engine search monetize as well as ten blue links? A wonderful franchise, watchfully owned.

A Buffett-lens X-ray of NVDA at $200: the best economics on the board — 63% net margins, revenue doubling, a real CUDA moat — but a cyclical, concentrated, unknowable decade and a $4.85T price that assumes permanence. A magnificent business that lands in the 'too hard' pile.

A Buffett-lens X-ray of KO at $80: the simplest 5/5 business on the board — a brand moat with 60+ years of dividend raises and Berkshire's 9% stake — but 25× earnings for ~6% growth keeps it a fair, not cheap, forever-hold.

A Buffett-lens X-ray of MSFT at $367: fortress balance sheet and a wide moat, now ~22× earnings — but owner earnings (~30×) and a thin margin of safety say keep watching.